Hexagon Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hexagon Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-73	Closed	-$17.8K	–	263
2025 Q1	$17.8K	Buy	73 +1	+1%	+$301	﹤0.01%	794
2024 Q4	$23.7K	Hold	72	–	–	﹤0.01%	733
2024 Q3	$24.1K	Hold	72	–	–	﹤0.01%	647
2024 Q2	$19.7K	Hold	72	–	–	﹤0.01%	691
2024 Q1	$24.9K	Hold	72	–	–	0.01%	616
2023 Q4	$23.2K	Hold	72	–	–	0.01%	587
2023 Q3	$25.8K	Hold	72	–	–	0.01%	495
2023 Q2	$27.3K	Hold	72	–	–	0.01%	483
2023 Q1	$34.5K	Hold	72	–	–	0.01%	426
2022 Q4	$30.3K	Hold	72	–	–	0.01%	452
2022 Q3	$30K	Hold	72	–	–	0.01%	496
2022 Q2	$36K	Hold	72	–	–	0.01%	424
2022 Q1	$41K	Hold	72	–	–	0.01%	397
2021 Q4	$54K	Hold	72	–	–	0.01%	351
2021 Q3	$54K	Hold	72	–	–	0.02%	337
2021 Q2	$46K	Hold	72	–	–	0.01%	339
2021 Q1	$41K	Hold	72	–	–	0.01%	327
2020 Q4	$41K	Hold	72	–	–	0.01%	293
2020 Q3	$42K	Buy	+72	New	+$36.5K	0.01%	273

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Hexagon Capital Partners's BIO Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 73 shares — an estimated $17.8K sold.

Hexagon Capital Partners first reported a position in BIO in Q3 2020 and held it in 19 quarters. The position peaked at $54K in Q4 2021. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Hexagon Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 73 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $17.8K.
Hexagon Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 19 quarters.
Hexagon Capital Partners's Bio-Rad Laboratories Class A position peaked at $54K in Q4 2021.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.